Results 121 to 130 of about 792 (225)
Beliefs and Belief-to-Behavior Inferences: Clarifications, Rebuttals, and Extensions. [PDF]
Samayoa JAG, Albarracín D.
europepmc +1 more source
Subject-matter and intensional operators I: conditional-agnostic analytic implication. [PDF]
Ferguson TM.
europepmc +1 more source
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim +3 more
wiley +1 more source
Is Reference a Relation of Equivalence or Sameness? [PDF]
Plazas EA.
europepmc +1 more source
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller +10 more
wiley +1 more source
An Information-Theoretic Model of Abduction for Detecting Hallucinations in Explanations. [PDF]
Galitsky B.
europepmc +1 more source
HiCL: Hierarchical Contrastive Learning of Unsupervised Sentence Embeddings. [PDF]
Wu Z, Xiao C, Vydiswaran VV.
europepmc +1 more source
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
PatientEase-Domain-Aware RAG for Rehabilitation Instruction Simplification. [PDF]
Nasimov R +8 more
europepmc +1 more source
BCL9 and BCL9L drive bladder cancer progression by enhancing β‐catenin signaling, promoting proliferation, migration, invasion, and organoid growth. Genetic depletion of BCL9(L) suppresses malignant phenotypes, while pharmacological disruption of the β‐catenin/BCL9(L) complex with ZW4864 inhibits canonical Wnt signaling and tumor‐associated cellular ...
Roland Kotolloshi +11 more
wiley +1 more source

